NCT02054572View on ClinicalTrials.gov

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 7, 2014

Primary Completion Date

April 15, 2014

Study Completion Date

August 15, 2014

Conditions

Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis

Interventions

DRUG

[¹⁴C]Etelcalcetide

750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.

Trial Locations (1)

55404

DaVita Clinical Research Center, Minneapolis